Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1602 • ACR Convergence 2022
Fibroblast Activation Protein (FAP) PET-CT for Depicting Inflammatory Joint Damage in Patients with Psoriatic Arthritis
Simon Rauber¹, Hashem Mohammadian², Chrstian Schmidkonz³, Armin Atzinger³, Maria Gabriella Raimondo¹, Hannah Labinsky⁴, Christoph Treutlein², Johannes Knitza¹, Simone Maschauer², Frank Roemer⁵, Olaf Prante², Torsten Kuwert³, Juan Canete⁶, Georg Schett⁷ and Andreas Ramming¹, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Erlangen, Germany, ³Friedrich-Alexander University (FAU) Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany, ⁶Unidad de Artritis Hospital Clinic, Barcelona, Spain, ⁷Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Psoriatic arthritis (PsA) is characterized by substantial mesenchymal tissue activation in the context of inflammation leading to structural damage. Measuring mesenchymal tissue activation in…
Abstract Number: 2113 • ACR Convergence 2022
Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies
Dennis McGonagle¹, Derek Haaland², Philip Helliwell³, A. Marilise Marrache⁴, May Shawi⁵, Emmanouil Rampakakis⁶, Peter Nash⁷, Fedra Irazoque Palazuelos⁸ and Arthur Kavanaugh⁹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²The Waterside Clinic, Oro Medonte, ON, Canada, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Janssen Inc., Dollard-des-Ormeaux, QC, Canada, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷School of Medicine, Griffith University, Sunshine Coast, Australia, ⁸Angeles Mocel Hospital; Universidad Autónoma de México, Ciudad de México, Mexico, ⁹University of California San Diego, La Jolla, CA
Background/Purpose: Despite available PsA treatments, a portion of PsA patients (pts) does not achieve improvements in PsA signs and symptoms according to ACR response criteria.…
Abstract Number: 2130 • ACR Convergence 2022
Apremilast in Bio-Naïve Patients with Early Psoriatic Arthritis: A National, Real-Life, Multicenter, Non-Interventional, Prospective, 52-week Cohort Study
Petros P. Sfikakis¹, Dimitrios Vassilopoulos², Gkikas Katsifis³, Georgios Vosvotekas⁴, Theodoros Dimitroulas⁵, Argyro Repa⁶, Grigorios Sakellariou⁷, THEODORA SIMOPOULOU⁸, Athanasios Georgountzos⁹, Andreas Bounas¹⁰, Panagiotis Georgiou¹¹, Evangelia Mole¹², Evangelia Kataxaki¹³, Stamatis Nick Liossis¹⁴, Evangelos Theodorou¹⁵, Christina Antoniadou¹⁶, EVANGELOS THEOTIKOS¹⁷, PANAYIOTIS VLACHOYIANNOPOULOS¹⁸, THEODORA MARKATSELI¹⁹, Angeliki Kekki²⁰, NIKOLAOS ANTONAKOPOULOS²¹ and Dimitrios Boumpas²², ¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ²Clinical Immunology-Rheumatology Unit, 2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece, ³Naval Hospital of Athens, Athens, Greece, ⁴Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ⁵4th Department of Internal medicine, Hippokration Hospital, School of medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ⁶Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Heraklion, Crete, Greece, ⁷Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece, Thessaloniki, Greece, ⁸Clinic of Rheumatology and Clinical Immunology, University Hospital of Larissa, Larissa, Greece, Larissa, Larisa, Greece, ⁹General Hospital of Athens G. Gennimatas, Athens, Greece, ¹⁰Olympion private General Clinic of Patras, Patras, Greece;, Patra, Akhaia, Greece, ¹¹Rheumatology Unit, Agios Andreas Hospital, Patras, Greece, PATRA, Akhaia, Greece, ¹²Department of Rheumatology, KAT General Hospital of Attica, Athens, Greece, ¹³Rheumatology Unit, Thriasio General Hospital of Elefsina, Magoula, Greece, ¹⁴Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Patras, Greece, Patras, Akhaia, Greece, ¹⁵Rheumatology Clinic 251 Hellenic Air Force Hospital, Athens, Greece, ¹⁶First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, ¹⁷Rheumatology Department, Asklepieion Voulas General Hospital, Athens, Greece, ¹⁸Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece, ¹⁹Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ²⁰Genesis Pharma SA, Halandri, Greece, ²¹Genesis Pharma SA, Chalandri, Greece, ²²4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Apremilast is a targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) approved for psoriatic arthritis (PsA). Few clinical studies assessing treatment regimens in PsA have focused…
Abstract Number: 2146 • ACR Convergence 2022
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years
Philip J Mease¹, Rodrigo Luppino Assad², Shigeyoshi Tsuji³, Pascal Richette⁴, Arathi Setty⁵, Erin McDearmon-Blondell⁶, Tianming Gao⁵, Sandra Ciecinski⁶ and Filip Van den bosch⁷, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil, ³Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, ⁴Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc., Mettawa, IL, ⁷Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium
Background/Purpose: Patients with psoriatic arthritis (PsA) who experience anti-TNF failure and switch to another TNF inhibitor as second- or third-line therapy typically show poorer responses…
Abstract Number: 0198 • ACR Convergence 2022
Patient Perspectives on Janus Kinase Inhibitor Use in the Treatment of Inflammatory Arthritis
Savia de Souza¹, Andrew Bassett², Ruth Williams² and Elena Nikiphorou³, ¹Independent, London, United Kingdom, ²King's College London, London, United Kingdom, ³Leiden University Medical Center & King's College London, London, United Kingdom
Background/Purpose: Janus kinase inhibitors (JAKi) have relatively recently been licensed to treat inflammatory arthritis (IA); specifically rheumatoid arthritis (RA) and psoriatic arthritis (PsA). They differ…
Abstract Number: 0402 • ACR Convergence 2022
Opioid Use and Healthcare Utilization in Adults with PsA and AS
Alexis Ogdie¹, Sofia Pedro², Jean Liew³ and Kaleb Michaud⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Boston University, Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Opioid use among individuals with spondyloarthritis is common, reported to be ~20-30% in some cohorts. Data on whether this subset of patients have higher…
Abstract Number: 1012 • ACR Convergence 2022
Comparison of Sacroiliac CT Findings in Patients with and Without Psoriatic Arthritis: Results of the CASIPSA Study
Olivier Fakih¹, Andre Ramon², Clément Prati¹, Paul Ornetti³, Daniel Wendling⁴ and Frank Verhoeven¹, ¹Service de rhumatologie, CHU de Besançon, Besançon, France, ²University Hospital of DIJON, Rheumatology, Dijon, France, ³Service de rhumatologie, CHU de Dijon, Dijon, France, ⁴CHU, University Teaching Hospital, Besançon, France
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with various rheumatological manifestations, such as arthritis or enthesitis, predominantly in the peripheral skeleton. However, the…
Abstract Number: 1039 • ACR Convergence 2022
Differential Retention of Adalimumab and Etanercept Biosimilars Compared to Originator Treatments: Results of a Retrospective French Multicentre Study
Guillaume LARID¹, Guy Baudens², Alexis DANDURAND¹, Pascal COQUERELLE³, Vincent Goeb⁴, Marie-Hélène Guyot⁵, Laurent Marguerie⁶, Frédéric MAURY⁷, Viellard Eric⁸, Eric Houvenagel⁹, Jean Hugues SALMON¹⁰, René-Marc Flipo¹¹ and elisabeth gervais¹, ¹CHU Poitiers, Poitiers, France, ²Private practice, Valenciennes, France, ³CH Béthune, Béthune, France, ⁴CHU Amiens, Amiens, France, ⁵Private practice, Roubaix, France, ⁶Institut Calot, Berck-Sur-Mer, France, ⁷Private practice, Béthune, France, ⁸Private practice, St. Malo, France, ⁹Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, ¹⁰Reims University Hospital, Reims, France, ¹¹CHU Lille, Boulogne-Billancourt, France
Background/Purpose: Studies have demonstrated equivalence in term of efficacy and safety of biosimilars (bsDMARDs) compared to the originals treatments (boDMARDs) and in switching situation. Less…
Abstract Number: 1235 • ACR Convergence 2022
Fibroblast Activation in Psoriasis Patients Assessed by 68Ga-FAPI-04 PET-CT Is Associated with Progression to Psoriatic Arthritis
Filippo Fagni¹, David Simon², Arnd Kleyer², Koray Tascilar², Jule Taubmann³, Sara Bayat¹, Ioanna Minopoulou³, Melek Yalcin Mutlu³, Armin Atzinger⁴, Torsten Kuwert⁴, Georg Schett⁵ and Chrstian Schmidkonz⁴, ¹University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³University Hospital Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ⁴Friedrich-Alexander University (FAU) Erlangen-Nuremberg, Erlangen, Germany, ⁵Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Prevalence of subclinical inflammatory lesions is high in patients with cutaneous psoriasis and constitutes a -risk constellation for the development of psoriatic arthritis (PsA)1.…
Abstract Number: 1498 • ACR Convergence 2022
The Association Between Sonographic Enthesitis with Sonographic Synovitis and Tenosynovitis in Psoriatic Arthritis
gavriel Balulu¹, Victoria Furer¹, Jonathan Wollman², David Levartovsky¹, Valerie Aloush¹, Ofir Elalouf¹, Hagit Sarbagil-Maman³, Liran Mendel², Sara Borok¹, Daphna Paran¹, Ori Elkayam³ and Ari Polachek¹, ¹Tel Aviv Medical Center, Tel Aviv, Israel, ²Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, ³Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Enthesitis is considered a hallmark of psoriatic arthritis (PsA). Ultrasound (US) is considered a more accurate tool for the assessment of enthesitis compared to…
Abstract Number: 1610 • ACR Convergence 2022
Are Serological Protease-mediated Peptides of Tissue Remodeling and Inflammation the New Disease Activity Biomarkers in Psoriatic Arthritis Patients?
Solveig S. Groen¹, Signe Holm Nielsen², Anne-Christine Bay-Jensen², Mozhgan Rasti³, Darshini Ganatra³, Katerina Oikonomopoulou³ and Vinod Chandran⁴, ¹Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ⁴Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Inflammatory and degenerative processes in the joint tissues are hallmarks of patients with psoriatic arthritis (PsA). Here, proteases play a major role in remodeling…
Abstract Number: 2114 • ACR Convergence 2022
Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study
Iain B McInnes¹, Enrique R Soriano², Lai-shan Tam³, Natalie Shiff⁴, May Shawi⁵, Emmanouil Rampakakis⁶ and Jeffrey Curtis⁷, ¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³The Chinese University of Hong Kong, Hong Kong, China, ⁴Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷University of Alabama at Birmingham, Division of Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Patients (pts) with PsA experience lower quality of life than both the general population and pts with psoriasis alone1,2. Recent PsA treatment recommendations highlight…
Abstract Number: 2131 • ACR Convergence 2022
Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis
Alen Zabotti¹, Sarah Ohrndorf², William Tillett³, Marlies Neuhold⁴, Michel van Speybroeck⁵, Elke Theander⁶, Christine Contré⁷, Mohamed Sharaf⁸, May Shawi⁹, Michelle Perate¹⁰, Alexa Kollmeier¹¹ and Pascal Richette¹², ¹Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁵Janssen Pharmaceutica, Beerse, Belgium, ⁶Janssen Cilag, Lund, Sweden, ⁷Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ⁸Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ⁹Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ¹⁰Janssen Scientific Affairs, LLC, Horsham, PA, ¹¹Janssen-Cilag, Research & Development, LLC, San Diego, CA, ¹²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19 subunit, demonstrated joint and skin efficacy in patients with active psoriatic arthritis (PsA) in the…
Abstract Number: 2148 • ACR Convergence 2022
Analysis of Serum Proteomics Data Identifies Beta-Defensin 2 as a Predictive Biomarker of Clinical Response to IL-17 Blockade in Psoriatic Arthritis
Mathias Cardner¹, Danny Tuckwell², Anna Kostikova², Pascal Forrer³, Richard Siegel², Alain Marti³, Marc Vandemeulebroecke³ and Enrico Ferrero², ¹Novartis Global Drug Development and Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Novartis Institutes for BioMedical Research, Basel, Switzerland, ³Novartis Global Drug Development, Basel, Switzerland
Background/Purpose: Despite several effective targeted therapies, biomarkers that predict whether a patient with psoriatic arthritis (PsA) will respond to a particular treatment are currently lacking.Methods:…
Abstract Number: 0199 • ACR Convergence 2022
Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
Peter Taylor¹, Frank Behrens², Philip J Mease³, Dieter Wetzel⁴, Paul Peloso⁵, Nicolai Brun⁴, Brian Wiens⁶, Jan Brandt-Juergens⁷, Edit Drescher⁸, Eva Dokoupilova⁹, Anna Rowińska-Osuch¹⁰, Nadia Abdel- Kader Martin¹¹ and Kurt de Vlam¹², ¹University of Oxford, Oxford, United Kingdom, ²Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴Affibody AB, Solna, Sweden, ⁵ACELYRIN, Naples, FL, ⁶ACELYRIN, Inc., Los Angeles, CA, ⁷Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁸Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, ⁹Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, ¹⁰ETG Network - Rheumatology, Warsaw, Poland, ¹¹Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, ¹²University Hospitals Leuven, Leuven, Belgium
Background/Purpose: Izokibep is a unique IL-17A inhibitor with high potency and small molecular size designed to overcome the limitations of monoclonal antibodies. IL-17 is a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].